Clinical trial · Observational
Microwave Ablation Versus Resection for Resectable Colorectal Liver Metastases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to prove that a strategy of first line local ablation of colorectal liver metastases with microwaves is not inferior to liver resections in terms of survival rates at three years with secondary endpoints being survival at five and ten years, interventional complication rates, length of stay, ablation precision measurements, need for further interventions and health-economic analysis. A cohort of 100 patients treated with CT guided microwave ablation of 1-5 metastases \<31mm in size will be followed and compared with propensity scored matched controls from the Swedish liver surgery registry - Sweliv. The study is a multi-institutional effort by the Hepato Pancreatico Biliary (HPB) units in Stockholm Sweden, Bern Switzerland and Groningen in the Netherlands.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasm Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Microwave ablation | Procedure | — | UNRESOLVED |
| Resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Ablation
- description
- Patients that are primarily treated with microwave ablation of colorectal liver metastases
- interventionNames
- Procedure: Microwave ablation
- label
- Resection
- description
- Patients identified in the Swedish liver registry during the same time frame subjected to liver resection, propensity score matched to the ablation group
- interventionNames
- Procedure: Resection
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 3 years
Secondary outcomes (9)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with 1-5 colorectal liver metastases * No metastases larger than 30 mm in diameter * All lesions amenable to CT-guided percutaneous microwave ablation * Patient also resectable * Patients so evaluated at the multidisciplinary tumor board meeting Exclusion Criteria: * Kidney failure excluding the use of iv contrast medium * Lack of informed consent * Logistic reasons where patient does not live in the region of the treatment centre
References
Publications (9)
- BACKGROUNDwww.livermetsurvey.com, annual statistics june 2014.
- BACKGROUNDCosti R, Leonardi F, Zanoni D, Violi V, Roncoroni L. Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist. World J Gastroenterol. 2014 Jun 28;20(24):7602-21. doi: 10.3748/wjg.v20.i24.7602. PMID 24976699
- BACKGROUNDPomfret EA, Pomposelli JJ, Gordon FD, Erbay N, Lyn Price L, Lewis WD, Jenkins RL. Liver regeneration and surgical outcome in donors of right-lobe liver grafts. Transplantation. 2003 Jul 15;76(1):5-10. doi: 10.1097/01.TP.0000079064.08263.8E. PMID 12865779
- BACKGROUNDDokmak S, Fteriche FS, Borscheid R, Cauchy F, Farges O, Belghiti J. 2012 Liver resections in the 21st century: we are far from zero mortality. HPB (Oxford). 2013 Nov;15(11):908-15. doi: 10.1111/hpb.12069. Epub 2013 Mar 6. PMID 23461811
- BACKGROUNDJones NB, McNally ME, Malhotra L, Abdel-Misih S, Martin EW, Bloomston M, Schmidt CR. Repeat hepatectomy for metastatic colorectal cancer is safe but marginally effective. Ann Surg Oncol. 2012 Jul;19(7):2224-9. doi: 10.1245/s10434-011-2179-0. Epub 2011 Dec 30. PMID 22207046
- BACKGROUNDNosher JL, Ahmed I, Patel AN, Gendel V, Murillo PG, Moss R, Jabbour SK. Non-operative therapies for colorectal liver metastases. J Gastrointest Oncol. 2015 Apr;6(2):224-40. doi: 10.3978/j.issn.2078-6891.2014.065. PMID 25830041
- BACKGROUNDPathak S, Jones R, Tang JM, Parmar C, Fenwick S, Malik H, Poston G. Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis. 2011 Sep;13(9):e252-65. doi: 10.1111/j.1463-1318.2011.02695.x. PMID 21689362
- BACKGROUNDOsaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res. 2015 Jan;45(1):59-74. doi: 10.1111/hepr.12378. Epub 2014 Jul 18.